Biotechnology is a broad discipline in ... for the controlled expression of therapeutics in engineered oncolytic bacteria, demonstrating significant anti-tumor efficacy in multiple tumor mouse ...

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic ...

CG Oncology has taken the ribbon for the first biotech initial public offering ... Cretostimogene grenadenorepvec is an oncolytic virus that is delivered directly into the bladder and is designed ...

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

That is the potential of oncolytic virus therapy, according to Chinese scientists working on the genetically engineered “tumour meltdown” treatment. They say these low-cost, high-impact ...

A biotech company based in Skokie ... However, rather than making beer, the technology uses bacteria to convert heat-trapping gases into fuels and chemicals. "Instead of eating sugar and making ...

A near-infrared optogenetic system was developed for the controlled expression of therapeutics in engineered oncolytic bacteria ... biology for environmental biotechnology, summarizing their ...

Here, BiomX is targeting at chronic pulmonary infections caused by Pseudomonas aeruginosa bacteria in cystic fibrosis patients. The nano-cap biotech was trading down 8% premarketing Monday morning.

The biotech sector is already buzzing with retail ... requirements and received FDA Orphan Drug Designation for MB-108, an oncolytic virus treatment for malignant glioma. While the stock fell ...

WOBURN, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies ...